133 related articles for article (PubMed ID: 17162252)
1. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
[TBL] [Abstract][Full Text] [Related]
2. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
[TBL] [Abstract][Full Text] [Related]
3. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice.
Hou G; Dick R; Abrams GD; Brewer GJ
J Lab Clin Med; 2005 Nov; 146(5):299-303. PubMed ID: 16242529
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
[TBL] [Abstract][Full Text] [Related]
5. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
6. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Brewer GJ
Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
Hou G; Abrams GD; Dick R; Brewer GJ
Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
[TBL] [Abstract][Full Text] [Related]
8. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
[TBL] [Abstract][Full Text] [Related]
9. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
[TBL] [Abstract][Full Text] [Related]
11. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model.
Brewer GJ; Dick R; Zeng C; Hou G
J Inorg Biochem; 2006 May; 100(5-6):927-30. PubMed ID: 16321443
[TBL] [Abstract][Full Text] [Related]
12. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
Brewer GJ
J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
[TBL] [Abstract][Full Text] [Related]
13. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.
Hou G; Dick R; Brewer GJ
Exp Biol Med (Maywood); 2009 Jun; 234(6):662-5. PubMed ID: 19307461
[TBL] [Abstract][Full Text] [Related]
14. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
Cox C; Teknos TN; Barrios M; Brewer GJ; Dick RD; Merajver SD
Laryngoscope; 2001 Apr; 111(4 Pt 1):696-701. PubMed ID: 11359142
[TBL] [Abstract][Full Text] [Related]
15. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice.
Osman AM; Nemnem MM; Abou-Bakr AA; Nassier OA; Khayyal MT
Food Chem Toxicol; 2009 Oct; 47(10):2425-30. PubMed ID: 19577608
[TBL] [Abstract][Full Text] [Related]
16. Metallothionein acts as a cytoprotectant against doxorubicin toxicity.
Kimura T; Fujita I; Itoh N; Muto N; Nakanishi T; Takahashi K; Azuma J; Tanaka K
J Pharmacol Exp Ther; 2000 Jan; 292(1):299-302. PubMed ID: 10604962
[TBL] [Abstract][Full Text] [Related]
17. Tetrathiomolybdate is partially protective against hyperglycemia in rodent models of diabetes.
Zeng C; Hou G; Dick R; Brewer GJ
Exp Biol Med (Maywood); 2008 Aug; 233(8):1021-5. PubMed ID: 18480419
[TBL] [Abstract][Full Text] [Related]
18. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.
Kim KK; Kawar NM; Singh RK; Lange TS; Brard L; Moore RG
Gynecol Oncol; 2011 Jul; 122(1):183-9. PubMed ID: 21529906
[TBL] [Abstract][Full Text] [Related]
19. S-allylcysteine ameliorates doxorubicin toxicity in the heart and liver in mice.
Mostafa MG; Mima T; Ohnishi ST; Mori K
Planta Med; 2000 Mar; 66(2):148-51. PubMed ID: 10763589
[TBL] [Abstract][Full Text] [Related]
20. The use of copper-lowering therapy with tetrathiomolybdate in medicine.
Brewer GJ
Expert Opin Investig Drugs; 2009 Jan; 18(1):89-97. PubMed ID: 19053885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
